Tissue and fluid penetration of garenoxacin in surgical patients

Surgical Infections

Volumn 8, Issue 2, 2007, Pages 179-187

  Edmiston, Charles E ^a   Krepel, Candace J ^a   Seabrook, Gary R ^a   Towne, Jonathan B ^a   Smith, Timothy L ^b   Loehrl, Todd A ^a   Wackym, P Ashley ^a   Johnson, Christopher P ^a   Otterson, Mary F ^a   Gajjar, Diptee A ^c   Krishna, Gopal ^d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GARENOXACIN;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; BILE; BODY FLUID; BONE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TISSUE LEVEL; ELECTROLYTE DISTURBANCE; FEMALE; GALLBLADDER; GLUCOSE BLOOD LEVEL; HUMAN; INTESTINE MUCOSA; LARGE INTESTINE; LIQUID CHROMATOGRAPHY; LIVER; MALE; MESENTERY LYMPH NODE; MINIMUM INHIBITORY CONCENTRATION; MUCOSA; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SKELETAL MUSCLE; SKIN INCISION; SMALL INTESTINE; SUBCUTANEOUS TISSUE; SURGICAL PATIENT; TANDEM MASS SPECTROMETRY; TISSUE WATER;

ADIPOSE TISSUE; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BONE AND BONES; CLINICAL TRIALS; DIGESTIVE SYSTEM; FEMALE; FLUOROQUINOLONES; HUMANS; LYMPH NODES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OTORHINOLARYNGOLOGIC SURGICAL PROCEDURES; SURGICAL PROCEDURES, ELECTIVE; TISSUE DISTRIBUTION;

EID: 34247189628     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2006.012     Document Type: Article

References (28)

1. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003;22:203-221.
2. Liebetrau A, Rodloff AC, Behra-Miellet J, Dubreuil L. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob Agents Chemother 2003;47:3667-3671.
3. Takahata M, Shimakura M, Hori R, et al. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother 2001;45:312-315.
4. Gajjar DA, Bello A, Ge Z, et al. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 2003;47:2256-2263.
5. Bello A, Hollenbaugh H, Gajjar D, et al. Ex vivo serum protein binding of BMS-284756: Impact on the unbound AUC/MIC ratio for Streptococcus pneumoniae. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. September 23-25, 2001, abstract no. A-45.
6. Stewart C, Gajjar D, Bello A, et al. Safety, tolerability and pharmacokinetics of BMS-284756, a novel Des-F(6)-quinolone, following 28 days of once daily oral dosing in healthy subjects. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. September 23-25, 2001, abstract no. A-46.
7. Andersson MI, MacGowan MP. Development of the quinolones. J Antimicrob Chemother 2003;51(Suppl S1):1-11.
8. Condon RE. Microbiology in intraabdominal infections: What is the message for clinical studies? [opinion paper]. Infection 1999;27:63-66.
9. DiPiro JT, Edmiston CE, Bohnen JM. Pharmacodynamics of antimicrobial therapy in surgery. Am J Surg 1996;171:615-622.
10. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997-1005.
11. Seabrook GR, Edmiston CE, Schmitt DD, et al. Comparison of serum and tissue antibiotic levels in diabetes-related foot infections. Surgery 1991;110:671-677.
12. Muller M, dela Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Distribution in tissue. Antimicrob Agents Chemother 2004;48:1441-1453.
13. U.S. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Federal Register 23 May 2001;66(100):28526-28537. Available at fda.gov/cder/guidance/4252.fnl.pdf
14. Belsley DA, Kuh E, Welsch R. Detecting influential observations and outliers. In: Besley DA, Kuh E, Welsch R, eds. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity. 2nd ed. New York. John Wiley & Sons, New York, 2004:6-30.
15. Statistical Analysis Systems (SAS). Version 6.12. SAS Institute, Inc. Cary, NC, 1996.
16. Liu P, Muller M, Derendorf H. Rational dosing of antibiotics: The use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 2002;19:285-290.
17. Edmiston CE, Suarez E, Walker A, et al. Penetration of ciprofloxacin and fleroxacin in biliary tract. Antimicrob Agents Chemother 1996;40:787-788.
18. Gehanno P, Darantiere S, Dubreuil C, et al. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother 2002;49:821-826.
19. Blondeau JM, Laskowski R, Bjarnason J, Stewart C. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 gram-negative and gram-positive organisms. Int J Antimicrob Agents 2000;14:45-50.
20. Otani T, Tanaka M, Ito E, et al. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob Agents Chemother 2003;47:3750-3759.
21. Nichols RL. The role of quinolones in abdominal surgery. Surg Infect 2000;1:65-72.
22. Edmiston CE, Krepel CJ, Kehl KS, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004;48:1012-1016.
23. Edmiston CE, Krepel CJ, Kehl KS, et al. Comparative in-vitro antimicrobial activity of a novel quinolone, garenoxacin against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J Antimicrob Chemother 2005;56:872-878.
24. Bassetti M, Dembry LM, Farrel PA, et al. Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates. Antimicrob Agents Chemother 2002;46:234-238.
25. Christiansen KJ, Bell JM, Turnidge JD, Jones RN. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001. Antimicrob Agents Chemother 2004;48:2049-2055.
26. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of the des-fluoro (6) quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. Antimicrob Agents Chemother 2002;46:866-870.
27. Hoellman DB, Kelly LM, Jacobs MR, Appelbaum PC. Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother 2001;45:589-592.
28. Weller TM, Andrews JM, Jevons G, Wise R. The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J Antimicrob Chemother 2002; 49:177-184.